Pascal Mäser

The paper introduces a high-throughput in vitro assay for evaluating antimalarial drug combinations and their pharmacodynamic interactions, showing improved efficiency and resolution compared to existing methods.

This paper uses human iPSC-derived macrophages to model T. cruzi infection and test trypanocidal compounds for Chagas disease drug discovery.

The paper shows that atovaquone and venturicidin A work together to kill Plasmodium falciparum by blocking two pathways that generate mitochondrial membrane potential.

This study shows venturicidin A targets ATP synthase in Trypanosoma brucei, causing mitochondrial membrane potential loss and kDNA loss, suggesting it as a potential antitrypanosomatid drug.